BioSpace News Archive

Gemina Labs Completes Influenza A/B Diagnostic Test Prototype

Gemina Laboratories Ltd. is pleased to announce the completion of its influenza A/B rapid test prototype.

January 6, 2023
·
5 min read
Business

LAVA Therapeutics Announces Appointment of New Directors to the Board

LAVA Therapeutics N.V., a clinical-stage immuno-oncology company focused on developing its proprietary Gammabody™ platform of bispecific gamma delta T cell engagers, announced the appointment of two new directors to its Board of Directors.

January 6, 2023
·
3 min read
FDA

Eisai’s Approach to U.S. Pricing for Leqembi™ (Lecanemab), a Treatment for Early Alzheimer’s Disease, Sets Forth Our Concept of “Societal Value of Medicine” in Relation to “Price of Medicine”

Based on hhc concept, our corporate philosophy, Eisai is committed to improve patients health outcomes and quality of life, simplify care delivery, increase health system efficiency and spur future investments in Alzheimer’s disease.

January 6, 2023
·
22 min read
FDA

FDA Grants Accelerated Approval for Alzheimer’s Disease Treatment

Today, the U.S. Food and Drug Administration approved Leqembi (lecanemab-irmb) via the Accelerated Approval pathway for the treatment of Alzheimer’s disease.

January 6, 2023
·
4 min read
Business

Ultragenyx Reports Preliminary 2022 Revenue; Guidance for 2023 Revenue and Cash Usage; Pipeline Updates and 2023 Milestones

Ultragenyx Pharmaceutical Inc. reported preliminary unaudited 2022 revenue results, cash and investments at year end 2022, and provided 2023 guidance on select key financial metrics including net cash used in operations.

January 6, 2023
·
9 min read
Lone Star Bio

Lexicon Pharmaceuticals to Participate in the 41st Annual JP Morgan Healthcare Conference

Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced its participation in the 41st Annual JP Morgan Healthcare Conference, taking place January 9-12, 2023.

January 6, 2023
·
3 min read
Pharm Country

Provention Bio Announces the Grant of Inducement Awards - Jan 06, 2023

Provention Bio, Inc., a biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, announced that the Company granted stock options to 58 non-executive employees to purchase an aggregate of 763,000 shares of common stock.

January 6, 2023
·
2 min read
Business

Haemonetics Sets Date for Publishing Third Quarter Fiscal Year 2023 Results: February 7, 2023

Haemonetics Corporation announced that the Company intends to publish third quarter fiscal year 2023 financial results at 6:00 am ET on Tuesday, February 7, 2023.

January 6, 2023
·
1 min read
Policy

FDA Roundup: January 6, 2023

The U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency.

January 6, 2023
·
3 min read
Bio NC

Science 37 Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) - Jan 06, 2023

Science 37 Holdings, Inc., the industry-leading Metasite™, announced the granting of an inducement equity award under the Science 37 Holdings, Inc. 2022 Employment Inducement Incentive Award Plan.

January 6, 2023
·
4 min read